Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Metrics to compare | PBM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPBMPeersSector | |
---|---|---|---|---|
P/E Ratio | 2.3x | −2.8x | −0.5x | |
PEG Ratio | 0.02 | 0.03 | 0.00 | |
Price/Book | 0.3x | 0.5x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.3x | |
Upside (Analyst Target) | - | 229.0% | 43.3% | |
Fair Value Upside | Unlock | 1.6% | 6.9% | Unlock |